Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01785771 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT01785771 is a Phase 3 study that was terminated before completion, run by Intarcia Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT01785771, a Phase 3 study, was terminated before completion, sponsored by Intarcia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day
Interventions
- DRUG ITCA 650 (exenatide in DUROS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-05 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01785771
The ClinicalTrials.gov registry entry for NCT01785771 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ITCA 650 (exenatide in DUROS) is the first listed.
NCT01785771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01785771 about?
NCT01785771 is a clinical study titled "A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c". An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 m...
What is the current status of trial NCT01785771?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2013-05. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01785771?
The interventions under investigation include: ITCA 650 (exenatide in DUROS) (DRUG).
Who is sponsoring clinical trial NCT01785771?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.